Clinical *Nocardia* species: Identification, clinical characteristics, and antimicrobial susceptibility in Shandong, China

Shu-Hua Lu[1#], Zhen-Wen Qian[1#], Pei-Pei Mou[2*], Lian Xie[2*]

ABSTRACT

Nocardia is a pathogen responsible for a variety of clinical infections. Here, we aimed to investigate the species distribution, clinical manifestations, and antimicrobial susceptibility of *Nocardia* species over 3 years in two tertiary general hospitals in China. In this retrospective study, a total of 27 *Nocardia* species were isolated from 27 individuals between January 2017 and December 2019. *Nocardia* isolates were identified to species level by mass spectrometry and 16S rRNA PCR sequencing. Clinical data were collected from medical records. Antimicrobial susceptibility was determined by the standard Broth microdilution method. The 27 patients with *Nocardia* infection included 12 males and 15 females with a mean age of 60.11 years. Among 27 *Nocardia* isolates, 7 species were identified, with the most common species being *Nocardia otitidiscaviarum* (40.7%). The antimicrobial susceptibility profiles varied between different *Nocardia* species. Notably, all *Nocardia* isolates were linezolid susceptible. The majority of *Nocardia* isolates were collected from a department of respiratory medicine (55.56%) and sputum specimen (44.44%). Pulmonary region was the most involved body site (70.37%) followed by skin (7.4%) and pleural cavity (7.4%). Most patients with *Nocardia* infection needed combination antibiotic therapy. Two deaths were reported during the treatment period and 24 patients achieved improvement after antibiotic therapy. The clinical manifestations of *Nocardia* infection and antimicrobial susceptibility profiles varied with diverse *Nocardia* species. Thus, the accurate identification of these species is crucial for the diagnosis and the selection of antibiotic treatment.

KEYWORDS: *Nocardia*; *Nocardia* infection; nocardiosis; antimicrobial susceptibility; mass spectrometry; identification

INTRODUCTION

Nocardia species, an aerobic actinomycete, exist in a wide range of environments around the world [1]. Currently, only a small proportion of described *Nocardia* species are known to be human pathogens that affect patients [2]. *Nocardia* species are facultative intracellular pathogens, which are capable of causing either a localized or disseminated infection both in immunocompetent and immunocompromised hosts [3]. In recent decades, an increased number of *Nocardia* infection cases have been reported worldwide [4]. *Nocardia* infection is characterized by a variety of clinical manifestations with the involvement of the lungs, central nervous system, skin, and other organs. More seriously, *Nocardia* can cause severe, life-threatening disseminated infections, such as osteomyelitis and nocardial sepsis [5,6]. Early recognition and effective therapy are imperative to achieve successful outcomes. Thus, elaboration of the molecular characteristics, infection, and clinical manifestations of *Nocardia* species is necessary for timely detection and diagnosis.

Despite numerous *Nocardia* species have been characterized both phenotypically and genotypically within the genus, the genotype remains heterogeneous and continues to evolve [7]. In addition, the genus of *Nocardia* is rapidly expanding and the species distribution varies with different geographical locations [8]. Reports about *Nocardia* species in China are limited to a few case reports, case series, and research studies [9-12]. Particularly, there is only limited information about the species distribution and drug susceptibility of *Nocardia* [12]. Thus, the present study was designed to identify *Nocardia* species using 16SrRNA and mass spectrometry (MS) in two tertiary hospitals in China and to investigate the species distribution, clinical manifestations, microbiological characteristics, and antimicrobial susceptibility of the *Nocardia* species. In addition, we retrospectively analyzed the therapeutic effects and prognosis of patients with *Nocardia* infection.

[1]Department of Clinical Laboratory, Affiliated Hospital of Jining Medical University, Jining, China
[2]Department of Clinical Laboratory, Shengli Oilfield Central Hospital, Dongying, China

*Corresponding authors: Lian Xie, Department of Clinical Laboratory, Shengli Oilfield Central Hospital, No. 31 Jinan Road, Dongying District, Dongying 257034, Shandong, China. Phone: +86-13156477528. E-mail: jingchao70@126.com
Pei-Pei Mou, Department of Clinical Laboratory, Shengli Oilfield Central Hospital, No.31 Jinan Road, Dongying District, Dongying 257034, Shandong, China. Phone: +86-18766769806. E-mail: peiyang9952@163.com
#These authors equally contributed

MATERIALS AND METHODS

Bacterial isolates

This retrospective study was conducted at two tertiary hospitals in China, namely, the Affiliated Hospital of Jining Medical University and the Shengli Oilfield Central Hospital. A total of 27 patients with culture-proven *Nocardia* infection from January 2017 through December 2019 were included in this analysis. *Nocardia* infection was defined as a positive culture in the presence of clinical and/or radiological features of infection. Ethics approvals were obtained from the participating centers. Clinical specimens, including sputum, broncho-alveolar lavage fluid (BALF), alveolar pus, and puncture fluid were incubated on the Columbia blood agar plates at 35°C for 3–7 days. The bacterial isolates were then stored at -80°C until used. The demographic characteristics, including age, years and diseases history, as well as clinical features, laboratory tests, therapeutic regimen and outcome of included patients, were retrospectively reviewed from the medical records.

Antimicrobial susceptibility tests

Antimicrobial susceptibility was determined using the standard Broth microdilution method following the recommendations of the Clinical and Laboratory Standards Institute (CLSI, 24th edition) [13]. Antibiotics were selected according to the first-line and second-line drugs used for *Nocardia* recommended in CLSI M24-2A, including amikacin (AMK), linezolid (LNZ), trimethoprim/sulfamethoxazole (TMP-SMX), ceftriaxone (CRO), ceftazidime (CAZ), cefepime (FEP), imipenem (IPM), tobramycin (TOB), moxifloxacin (MOX), ciprofloxacin (CIP), clarithromycin (CLA), amoxicillin-clavulanic acid (AMC), and minocycline (MIN). The antibiotic susceptibility was judged as susceptible, intermediate, or resistant based on the breakpoints recommended in CLSI M24-2A. *Escherichia coli* ATCC 25922 and *Staphylococcus aureus* ATCC 25923 were used as controls.

Identification of *Nocardia* species

Initial presumptive identification was performed according to the colony morphology on solid medium, Gram stain appearance, acid-fast staining and modified acid-fast staining, following the standard protocol. White colonies on culture plates, branching Gram-positive bacilli, positive acid-fast staining, and positive partial acid-fast staining were identified as *Nocardia* species.

Nocardia species were further verified by MS identification using an automated VITEK-MS system (BioMerieux, Marcy l'Etoile, France). Briefly, the bacteria isolates were mixed with 0.5 mm glass beads containing 70% ethanol (500 μL) in a pre-sterilized centrifuge tube and incubated at room temperature for 10 min. Then, the suspension was transferred into a 2.0 mL tube and centrifuged at 14,000 × g for 2 min. After ethanol was removed, the bacteria isolates were resuspended with 70% formic acid (10 μL) followed by acetonitrile (10 μL) for protein extraction. Next, the suspension was centrifuged at 14,000 × g for 2 min again and 1 μL supernatant was transferred onto target slide. After drying, 1 μL α-cyano-4-hydroxycinnamic acid (CHCA) matrix was added to complete the process. Results were analyzed using the VITEK-MS system with knowledgebase 3.0.

Bacterial genotypic identification of *Nocardia* species was further performed by 16S rRNA gene polymerase chain reaction (PCR) analysis. DNA was prepared using Bacterial Genomic DNA Extraction Kit according to the manufacturer's instructions (TIANGEN, Beijing, China). The primer sequences of 16S rRNA used were as follows: forward primer (5′-AGAGTTTGATCCTGGCTCAG-3′) and reverse primer (5′-GGTTACCTTGTTACGACTT-3′). PCR reactions were conducted with a total reaction volume of 25 μL per well containing Phanta Max Master Mix (12.5 μL, Vazyme, Nanjing, China), forward and reverse primer (each 0.5 μL), DNA template (2.5 μL), and RNase-free water (9 μL). Amplification was performed using Veriti Thermal Cycler (Applied Biosystems, USA) under the following conditions: 95°C for 2 min, followed by 30 cycles of 95°C for 30 s, 55°C for 30 s, and 72°C for 30 s. PCR product identity was confirmed by BLAST searches of the GenBank database (https://blast.ncbi.nlm.nih.gov/Blast.cgi). Species identification results of 16S rRNA with at least 99.0% similarity were regarded as positive.

Statistical analysis

All statistical analyses were performed by IBM SPSS Statistics for Windows, Version 22.0. (IBM Corp., Armonk, NY, USA). Quantitative data were presented by mean ± standard deviation (SD). Qualitative data were described by number or percentage.

RESULTS

Demographic characteristics

A total of 27 *Nocardia* isolates were identified in two centers in China during January 2017–December 2019. The demographic characteristics of patients are summarized in Table 1. There were 12 males and 15 females with a mean age (± SD) of 60.11 ± 14.94 years (median, 60 years and range, 24–87 years) identified as culture-positive *Nocardia* infection. The majority of patients (25/27, 92.6%) showed at least one underlying disease, including type 2 diabetes mellitus (7 cases), hypertension (6 cases), chronic obstructive pulmonary disease (COPD, 6 cases), bronchiectasis (5 cases), rheumatic immune diseases

(5 cases), heart failure (2 cases), renal insufficiency (2 cases), malignant tumor (2 cases), and cerebral infarction (1 case).

Phenotype identification of *Nocardia* species

Phenotype identification of *Nocardia* species was performed by colony morphology, Gram staining, acid-fast staining, and modified acid-fast staining. Bacterial cultures showed that *Nocardia* species were aerobic, but with a slow reproduction rate. It generally takes 3–5 days to form visible

TABLE 1. Baseline characteristics of included patients

Baseline characteristics	Patients
Gender n (%)	
Male	12 (44.44)
Female	15 (55.56)
Age (years)	
Median (range)	60 (24–87)
Mean±SD	60.11±14.94
Diseases history n (%)	
Yes/No	25 (92.59)/2 (7.41)
Underlying disease n	
Type 2 diabetes mellitus	7
Hypertension	6
Chronic obstructive pulmonary disease	6
Bronchiectasis	5
Rheumatic immune diseases	5
Heart failure	2
Renal insufficiency	2
Malignant tumor	2
Cerebral infarction	1

colonies and present as white, yellow, or orange colonies on culture plates (Figure 1A). Clinical isolates with branching Gram-positive bacilli (Figure 1B), negative acid-fast staining (Figure 1C), and positive partial acid-fast staining (Figure 1D) were identified as *Nocardia* species.

Molecular identification and distribution of *Nocardia* species

The 27 *Nocardia* isolates were firstly identified using the automated VITEK-MS system. Among the 27 *Nocardia* isolates, 7 species and 1 genus were confirmed. The representative MS identification results are shown in Figure 2. *N. otitidiscaviarum* was the most common species, accounting for 40.7% (11/27), followed by *N. cyriacigeorgica* (25.9%, 7/27), *N. brasiliensis* (11.1%, 3/27), *N. asteroides* (7.4%, 2/27), *N. wallacei* (3.7%, 1/27), *N. farcinica* (3.7%, 1/27), and *N. abscessus* (3.7%, 1/27). One *Nocardia* isolate has not been identified as a species by MS identification.

The *Nocardia* isolates were further confirmed by 16S rRNA PCR sequencing. A total of 7 species were identified, which was generally consistent with the results of MS identification, including *N. otitidiscaviarum* (40.7%,11/27), followed by *N. cyriacigeorgica* (25.9%, 7/27), *N. brasiliensis* (11.1%, 3/27), *N. asteroids* (7.4%, 2/27), *N. wallacei* (7.4%, 2/27), *N. farcinica* (3.7%, 1/27), and *N. abscessus* (3.7%, 1/27), respectively.


FIGURE 1. Phenotype identification of *Nocardia* species. (A) Colonies of *Nocardia* cultured on blood agar plates for 5 days and appearing as white, yellow, or orange colonies on culture plates. (B) Clinical isolates with branching Gram-positive bacilli (magnification, ×100). (C) Clinical isolates with negative acid-fast staining (magnification, ×100). (D) Clinical isolates with positive partial modified acid-fast staining (magnification, ×100).

FIGURE 2. *Nocardia* isolates were identified by mass spectrometry, 7 species and 1 genus were confirmed. Representative mass spectrometry identification results of *Nocardia* species are shown: (A) *Nocardia otitidiscaviarum*; (B) *Nocardia cyriacigeorgica*; (C) *Nocardia brasiliensis*; and (D) *Nocardia abscessus*.

Antimicrobial susceptibility

The susceptibility to 13 kinds of commonly-used antibiotics for *Nocardia* species is shown in Figure 3. *Nocardia* isolates showed a high sensitivity rate to AMK (92.59%), LNZ (100%), TMP-SMX (96.30%), TOB (88.89%), and MIN (81.48%). Meanwhile, *Nocardia* isolates were highly resistant to CAZ (69.26%), FEP (69.26%), CLA (92.59%), and AMC (74.07%). Notably, all of the isolates were LNZ susceptible. With regard to each *Nocardia* isolate, different *Nocardia* species had different antimicrobial susceptibility profiles, as shown in Figure 3. For example, all *N. otitidiscaviarum* isolates were highly sensitive to AMK, LNZ, TMP-SMX, TOB, CIP and MIN, while resistant to CRO, CAZ, FEP, IMP, CLA, and AMC. *N. cyriacigeorgica* isolates were sensitive to AMK, LNZ, TMP-SMX, IMP, TOB and MIN, while resistant to MOX, CIP, CLA and AMC.

Clinical characteristics

Clinical characteristics of patients are summarized in Table 2. Patients with culture-proven *Nocardia* infection were distributed in various departments of our hospital but mostly in the Department of Respiratory Medicine (15/27, 55.56%). Besides, patients were distributed in the intensive care unit and the departments of rheumatology and immunology, orthopedics, stomatology, thoracic surgery, infection, vascular surgery, and urology. Among the 27 *Nocardia* isolates, 12 (44.44%) isolates were collected from sputum, 5 (18.52%) from BALF, 5 (18.52%) from alveolar pus, 3 (11.11%) from puncture fluid, and 2 (7.41%) were from the bronchial brush. At the time of diagnosis, high-sensitivity C-reactive

TABLE 2. Clinical characteristics of included patients

Characteristics	Patients
Department n (%)	
Respiratory medicine	15 (55.56)
Intensive care unit	3 (11.11)
Rheumatology and immunology	2 (7.41)
Orthopedics	2 (7.41)
Stomatology	1 (3.70)
Thoracic surgery	1 (3.70)
Infection	1 (3.70)
Vascular surgery	1 (3.70)
Urology	1 (3.70)
Specimen type n (%)	
Sputum	12 (44.44)
Bronchoalveolar lavage fluid	5 (18.52)
Alveolar pus	5 (18.52)
Puncture fluid	3 (11.11)
Bronchial brush	2 (7.41)
Involved site	
Lung	19 (70.37)
Skin	2 (7.41)
Pleural cavity	2 (7.41)
Kidney	1 (3.70)
Joint	1 (3.70)
Maxillofacial region	1 (3.70)
Soft tissue	1 (3.70)

protein (hs-CRP) and procalcitonin (PCT) assay was performed in 27 patients. The results showed that 21 patients had a positive CRP finding (CRP ≥8 mg/L) and 6 patients had a positive PCT finding (PCT ≥0.5 ng/mL). In addition, one patient was hemoculture positive. Lung was the most involved body site (19/27, 70.37%), followed by skin (2/27, 7.41%), pleural cavity (2/27, 7.41%), kidney (1/27, 3.70%), joint (1/27, 3.70%), maxillofacial region (1/27, 3.70%), and soft tissue (1/27, 3.70%).

FIGURE 3. Antimicrobial susceptibility of *Nocardia* species was determined using the standard Broth microdilution method. Antimicrobial susceptibility results of 7 *Nocardia* species showed that different *Nocardia* species had different antimicrobial susceptibility profiles, but all of the isolates were LNZ susceptible. AMK: Amikacin; LNZ: Linezolid; TMP-SMX: Trimethoprim/sulfamethoxazole; CRO: Ceftriaxone; CAZ: Ceftazidime; FEP: Cefepime; IPM: Imipenem; TOB: Tobramycin; MOX: Moxifloxacin; CIP: Ciprofloxacin; CLA: Clarithromycin; AMC: Amoxicillin-clavulanic acid; MIN: Minocycline.

Treatment and outcome

Treatment information was available for all included patients. Among them, 2 patients were administrated with TMP-SMX monotherapy and 24 were administrated with the combination of TMP-SMX and other antibacterial agents such as MIN, AMK, etimicin sulfate, CIP, LNZ, and MOX. One patient was administrated with combination therapy of LNZ and cephalosporins because of allergy to sulfonamides. The treatment duration in surviving patients ranged from 7 days to 6 months. The duration of treatment in the majority of patients (81.48%) was 3 months. During treatment, no patient had abnormal blood test results nor the dysfunction of liver and kidney. Two patients experienced gastrointestinal discomfort and were relieved after omeprazole administration. Another patient had leukocytopenia and received treatment with Diyushengbai tablet. After treatment, a total of 24 patients achieved improvement and were discharged. Two deaths were reported during the treatment period. Another patient repeatedly experienced *Nocardia* infection and had been hospitalized 3 times for *Nocardia* infection of the joint until December 31, 2019.

DISCUSSION

Previous reports indicated an increasing trend of *Nocardia* infection over the past decade [4]. In addition, *Nocardia* species are distributed differently across various geographic regions. Thus, it is necessary to investigate the epidemiology, clinical characteristics, and antimicrobial susceptibility of *Nocardia* species in different geographic regions, especially in China, a region with various geographical and climatic characteristics. Here, a total of 27 *Nocardia* isolates were obtained from 27 individuals between 2017 and 2019 at two centers in Shandong province, China. In previous studies, Yang et al. reported 40 cases with nocardiosis in a 14-year observational study between 2000 and 2013 [14] and Huang et al. analyzed 53 cases over 9 years from 2009 to 2017 [12]. Based on this evidence, we speculated that *Nocardia* infection occurred more frequently in our two centers over the past 3 years, in accordance with the overall epidemiological trends of *Nocardia* infection.

To date, more than 80 species of *Nocardia* have been described and 50 species have been identified to be human pathogens [8,12]. Nevertheless, only a few species can be reliably identified by the traditional biochemical methods, including *N. farcinica*, *N. brasiliensis*, *N. asteroides* and *N. pseudobrasiliensis* [7]. In general, the traditional biochemical methods are very time-consuming, resulting in a delayed diagnosis of infection. In recent years, 16S rRNA gene sequencing technique has become a reliable method for *Nocardia* identification [15]. However, the high cost and lack of standardization have been the major obstacle for the application of 16S rRNA gene sequencing in China. Notably, matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS has emerged as an alternative method in the routine laboratory identification of *Nocardia* [16] and also has been widely applied in a large number of tertiary general hospitals in China [17]. In our study, we performed both the sequencing of 16S rRNA gene and MALDI-TOF MS to identify *Nocardia* species and obtained consistent identification

results. Only one strain of *N. wallacei* was not identified to the specific species level by MS and whether this was due to technical operation or the limitations of MS remains to be further confirmed. Overall, MS has the potential to be a reliable technique for the identification of *Nocardia* species, according to the experience at our centers.

In the present study, a total of 7 *Nocardia* species were identified, of which *N. otitidiscaviarum* was the most frequently isolated, followed by *N. cyriacigeorgica*. Inconsistently, in previous studies, the predominant *Nocardia* species varied in different regions; namely, *N. nova*, *N. abscessus* and *N. cyriacigeorgica* were, respectively, the most predominant species in the United States [18], Italy [19], and Spain [20]. Even in China, the distributional features of *Nocardia* species varied in different regions [12,21-23], indicating that the distribution of *Nocardia* species might be geographically-related.

Treatment for *Nocardia* infection according to the susceptibility of the isolated species is essential whenever possible, thereby, understanding the species-specific antimicrobial susceptibility patterns is very important. We reported the antimicrobial susceptibility patterns of the first-line and second-line drugs used for *Nocardia* infection. Here, the antimicrobial susceptibility profile was largely consistent with the results of the antibiograms available in the literature [19,22]. We found that the *Nocardia* species had good susceptibility to LNZ, TMP-SMX, and AMK in the present study. Furthermore, our isolates showed varying susceptibilities to different antibiotics. However, each species had a limited number of strains, which may not be enough to accurately represent the antimicrobial susceptibility. Thus, further studies with a larger sample size are still needed to confirm the antibiograms from our region.

In general, the majority of patients with *Nocardia* infection have a certain degree of immune deficiency, particularly patients with underlying diseases or immunosuppressive treatment. In the present study, approximately 93% of patients had at least one known underlying disease responsible for immune deficiency, which was consistent with the previous data [4,23]. The most common underlying diseases were type 2 diabetes mellitus, hypertension, and COPD. It is reported that impaired local pulmonary deficiency caused by COPD predispose to pulmonary nocardiosis, particularly in patients requiring long-term corticosteroid treatment [24]. Among the 27 included cases, 2 (7.41%) cases showed no evidence of underlying diseases. This data ranges from 10% to 25% in other reports [4]. Thus, *Nocardia* infection can occur both in immunocompetent and immunocompromised hosts.

With regard to the site of involvement, the pulmonary region was the most commonly involved body site of the patients in our two centers, which is consistent with the previous findings [14,19]. In addition, a literature review that included more than 1000 patients also reported that the pulmonary apparatus was the most commonly involved site [25]. In fact, it is well known that, because of its transmission route (direct inhalation or inoculation), *Nocardia* infections are mainly localized in the lower respiratory tract and the soft tissue. Nevertheless, nocardiosis is mostly an opportunistic infection leading to severe, life-threatening disseminated infections. Occasionally, some patients with disseminated infection may show the brain abscess, brain involvement, or neurological deficits [26,27]. No brain involvement was reported in our retrospective analysis, however, this may be due to the small sample size and the possibility should not be discounted. These findings suggest that either lung or brain computed tomography should be performed routinely in patients with *Nocardia* infections.

The laboratory test results were available in all 27 patients and showed that most patients had positive hs-CRP and approximately 20% of patients had positive PCT. Similarly, Guo et al. reported that most patients with nocardiosis had an elevated CRP level, whereas PCT levels were normal or slightly elevated [28]. These results suggest some typical indicators of *Nocardia* infection and increasing PCT levels may indicate a severe infection.

At present, antibiotic treatment is a major therapeutic strategy for *Nocardia* infection and, among them, TMP-SMX has been preferred and used as the first-line therapy [29]. For some patients with a serious infection and long duration, TMP-SMX-based combination therapy is recommended in clinical setting [30]. Unfortunately, an optimal therapeutic strategy has not been well defined in clinical practice. In the present study, TMP-SMX was the most commonly administered treatment and is still considered as a primary treatment option at our centers. The majority of our patients received TMP-SMX-based combination therapy. Recently, LNZ showed favorable clinical effectiveness in *Nocardia* infections, and it has the potential to be a useful alternative therapeutic agent due to its oral availability and activity against most *Nocardia* species [31]. In our study, since one patient was allergic to SMX, the combination therapy of LNZ and cephalosporins was administrated. After the corresponding therapy, nearly 90% of our patients achieved improvement and were discharged. The mortality rates associated with *Nocardia* infection reported in the literature range from 26% to 63% [32]. The mortality rate was 7.41% in our study, which is at a relatively low level. It is demonstrated that the mortality rate depends on the underlying disease, degree of immunosuppression, and disseminated form of *Nocardia* infection [33]. The clinical course of one patient in the present study, who experienced recurrent infection during treatment, was very complicated. This case suggested that follow-up treatment is necessary and may protect against relapses and dissemination.

CONCLUSION

The present study retrospectively analyzed 27 non-repetitive clinical *Nocardia* isolates from two centers in Shandong, China. We found that the clinical manifestations of *Nocardia* infection and antimicrobial susceptibility profiles varied with different *Nocardia* species. Besides, MALDI-TOF MS was proved as a rapid and accurate identification for the *Nocardia* species. Our findings suggest the necessity of accurate species identification and confirmation of antimicrobial susceptibility patterns in the diagnosis and the choice of antibiotic treatment.

ACKNOWLEDGMENTS

REFERENCES

[1]   Dhakal D, Jha AK, Pokhrel A, Shrestha A, Sohng JK. Genetic manipulation of *Nocardia* species. Curr Protoc Microbiol 2016;40(1):10F.2.1-10F.2.18.
https://doi.org/10.1002/9780471729259.mc10f02s40.

[2]   Hashemi-Shahraki A, Heidarieh P, Bostanabad SZ, Hashemzadeh M, Feizabadi MM, Schraufnagel D, et al. Genetic diversity and antimicrobial susceptibility of *Nocardia* species among patients with nocardiosis. Sci Rep 2015;5(1):17862.
https://doi.org/10.1038/srep17862.

[3]   Bafghi MF, Eshraghi SS, Heidarieh P, Habibnia S, Nasab MR. Nocardiosis in immune disorder disease. Malays J Med Sci 2014;21(1):75-6.

[4]   Matulionyte R, Rohner P, Uckay I, Lew D, Garbino J. Secular trends of *Nocardia* infection over 15 years in a tertiary care hospital. J Clin Pathol 2004;57(8):807-12.
https://doi.org/10.1136/jcp.2004.016923.

[5]   Vanegas S, Franco-Cendejas R, Cicero A, Lopez-Jacome E, Colin C, Hernández M. *Nocardia brasiliensis*-associated femorotibial osteomyelitis. Int J Infect Dis 2013;20:63-5.
https://doi.org/10.1016/j.ijid.2013.11.002.

[6]   McGuinness SL, Whiting SE, Baird R, Currie BJ, Ralph AP, Anstey NM, et al. Nocardiosis in the tropical Northern territory of Australia, 1997-2014. Open Forum Infect Dis 2016;3(4):ofw208.
https://doi.org/10.1093/ofid/ofw208.

[7]   Brown-Elliott BA, Brown JM, Conville PS, Wallace RJ Jr. Clinical and laboratory features of the *Nocardia* spp. Based on current molecular taxonomy. Clin Microbiol Rev 2006;19(2):259-82.
https://doi.org/10.1128/cmr.19.2.259-282.2006.

[8]   Tan CK, Lai CC, Lin SH, Liao CH, Chou CH, Hsu HL, et al. Clinical and microbiological characteristics of nocardiosis including those caused by emerging *Nocardia* species in Taiwan, 1998-2008. Clin Microbiol Infect 2010;16(7):966-72.
https://doi.org/10.1111/j.1469-0691.2009.02950.x.

[9]   Wu J, Wu Y, Zhu Z. Pulmonary infection caused by *Nocardia cyriacigeorgica* in a patient with allergic bronchopulmonary aspergillosis: A case report. Medicine 2018;97(43):e13023.
https://doi.org/10.1097/md.0000000000013023.

[10] Yu S, Wang J, Fang Q, Zhang J, Yan F. Specific clinical manifestations of *Nocardia*: A case report and literature review. Exp Ther Med 2016;12(4):2021-6.
https://doi.org/10.3892/etm.2016.3571.

[11] Yu X, Han F, Wu J, He Q, Peng W, Wang Y, et al. *Nocardia* infection in kidney transplant recipients: Case report and analysis of 66 published cases. Transplant Infect Dis 2011;13(4):385-91.
https://doi.org/10.1111/j.1399-3062.2011.00607.x.

[12] Huang L, Chen X, Xu H, Sun L, Li C, Guo W, et al. Clinical features, identification, antimicrobial resistance patterns of *Nocardia* species in China: 2009-2017. Diagn Microbiol Infect Dis 2019;94(2):165-72.
https://doi.org/10.1016/j.diagmicrobio.2018.12.007.

[13] Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: 22th Informational Supplement. Wayne, PA: Clinical Laboratory Standards Institute; 2012.

[14] Yang M, Xu M, Wei W, Gao H, Zhang X, Zhao H, et al. Clinical findings of 40 patients with nocardiosis: A retrospective analysis in a tertiary hospital. Exp Ther Med 2014;8(1):25-30.
https://doi.org/10.3892/etm.2014.1715.

[15] Conville PS, Fischer SH, Cartwright CP, Witebsky FG. Identification of *Nocardia* species by restriction endonuclease analysis of an amplified portion of the 16S rRNA gene. J Clin Microbiol 2000;38(1):158-64.
https://doi.org/10.1128/JCM.38.1.158-164.2000.

[16] Carrasco G, de Dios Caballero J, Garrido N, Valdezate S, Cantón R, Sáez-Nieto JA. Shortcomings of the commercial MALDI-TOF MS database and use of MLSA as an arbiter in the identification of *Nocardia* species. Front Microbiol 2016;7(542):7.
https://doi.org/10.3389/fmicb.2016.00542.

[17] Wei M, Wang P, Yang C, Gu L. Molecular identification and phylogenetic relationships of clinical *Nocardia* isolates. Antonie van Leeuwenhoek 2019;112(12):1755-66.
https://doi.org/10.1007/s10482-019-01296-2.

[18] Uhde KB, Pathak S, McCullum I Jr., Jannat-Khah DP, Shadomy SV, Dykewicz CA, et al. Antimicrobial-resistant *Nocardia* isolates, United States, 1995-2004. Clin Infect Dis 2010;51(12):1445-8.
https://doi.org/10.1086/657399.

[19] Mazzaferri F, Cordioli M, Segato E, Adami I, Maccacaro L, Sette P, et al. Nocardia infection over 5 years (2011-2015) in an Italian tertiary care hospital. New Microbiol 2018;41(2):136-40.

[20] Valdezate S, Garrido N, Carrasco G, Medina-Pascual MJ, Villalón P, Navarro AM, et al. Epidemiology and susceptibility to antimicrobial agents of the main *Nocardia* species in Spain. J Antimicrob Chemother 2017;72(3):754-61.
https://doi.org/10.1093/jac/dkw489.

[21] Xiao M, Pang L, Chen SC, Fan X, Zhang L, Li HX, et al. Accurate identification of common pathogenic *Nocardia* species: Evaluation of a multilocus sequence analysis platform and matrix-assisted laser desorption ionization-time of flight mass spectrometry. PLoS One 2016;11(1):e0147487.
https://doi.org/10.1371/journal.pone.0147487.

[22] Wei M, Wang P, Qu J, Li R, Liu Y, Gu L, et al. Identification and antimicrobial susceptibility of clinical *Nocardia* species in a tertiary hospital in China. J Glob Antimicrob Resist 2017;11:183-7.
https://doi.org/10.1016/j.jgar.2017.08.011.

[23] Yi M, Wang L, Xu W, Sheng L, Jiang L, Yang F, et al. Species distribution and antibiotic susceptibility of *Nocardia* isolates from Yantai, China. Infect Drug Resist 2019;12:3653-61.
https://doi.org/10.2147/idr.s232098.

[24] Zia K, Nafees T, Faizan M, Salam O, Asad SI, Khan YA, et al. Ten year review of pulmonary nocardiosis: A series of 55 cases. Cureus 2019;11(5):e4759.
https://doi.org/10.7759/cureus.4759.

[25] McNeil MM, Brown JM. The medically important aerobic actinomycetes: Epidemiology and microbiology. Clin Microbiol Rev 1994;7(3):357-417.
https://doi.org/10.1128/cmr.7.3.357-417.1994.

[26] Tauziede-Espariat A, Sharer LR. Cerebral nocardiosis. In: Chrétien F, Wong KT, Sharer LR, Keohane C, Gray F, editors. Infections of the Central Nervous System. Hoboken, United States: John Wiley and Sons Ltd; 2020. p. 343-7.
https://doi.org/10.1002/9781119467748.ch35.

[27] Majeed A, Abdullah HM, Ullah W, Al Mohajer M. First reported

case of disseminated *Nocardia kroppenstedtii* sp nov. Infection presenting with brain abscess and endocarditis in an immunocompromised patient with mantle cell lymphoma: Challenges in diagnosis and treatment. Case Rep 2017;2017:bcr2016217337.
https://doi.org/10.1136/bcr-2016-217337.

[28] Guo J, Li S, Xu S, Jiang L, Gao E, Liu Z. Nocardiosis in patients with nephrotic syndrome: A retrospective analysis of 11 cases and a literature review. Int Urol Nephrol 2020;52(4):731-8.
https://doi.org/10.1007/s11255-020-02415-z.

[29] Ambrosioni J, Lew D, Garbino J. Nocardiosis: Updated clinical review and experience at a tertiary center. Infection 2010;38(2):89-97.
https://doi.org/10.1007/s15010-009-9193-9.

[30] Arasaratnam RJ, Restrepo A. *Nocardia* infections in transplantation: Diagnosis, management, and impact on outcomes. In: Morris M, Kotton C, Wolfe C, editors. Emerging Transplant Infections. Springer, Cham; 2020. p. 1-18.
https://doi.org/10.1007/978-3-030-01751-4_18-1.

[31] Davidson N, Grigg MJ, Mcguinness SL, Baird RJ, Anstey NM, editors. Safety and Outcomes of Linezolid Use for Nocardiosis. Open Forum Infectious Diseases. United States: Oxford University Press; 2020.
https://doi.org/10.1093/ofid/ofaa090.

[32] Khan BA, Duncan M, Reynolds J, Wilkes DS. *Nocardia* infection in lung transplant recipients. Clin Transplant 2008;22(5):562-6.
https://doi.org/10.1111/j.1399-0012.2008.00824.x.

[33] Haussaire D, Fournier PE, Djiguiba K, Moal V, Legris T, Purgus R, et al. Nocardiosis in the south of France over a 10-years period, 2004-2014. Int J Infect Dis 2017;57:13-20.
https://doi.org/10.1016/j.ijid.2017.01.005.

Related articles published in BJBMS

1. Methicillin-Resistant Staphylococcus Aureus (MRSA) as a cause of nosocomial wound infections

   Maida Šiširak et al., BJBMS, 2010

2. Analysis of multidrug-resistant bacteria in 3223 patients with hospital-acquired infections (HAI) from a tertiary general hospital in China

   Meng Wang et al., BJBMS, 2019